Adam Simmons, MPH

Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit, Burden, and Satisfaction in Patients With Schizophrenia

Background: An open-label extension study (NCT02873208) evaluated the long-term tolerability, safety, and efficacy of combination olanzapine/samidorphan (OLZ/SAM) treatment in patients wi...

Leona Bessonova , PhD;

Amy O'Sullivan , PhD;

David McDonnell , MD;

Cory Saucier , MPH;

Michelle White , PhD;

April Foster , BS;

Jakob Bjorner , MD, PhD;

Olga Lapeyra , MD, CCRP;

David Walling , PhD, CNS, MD;

Adam Simmons , MPH;

Julia Carpenter-Conlin , MSW;

10/08/2020

Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients With Schizophrenia: The 1 Year ENLIGHTEN-2-Extension

Background: Combination olanzapine and samidorphan (OLZ/SAM) is in development for treatment of schizophrenia and bipolar I disorder and is intended to provide the antipsychotic efficacy ...

Bei Yu , PhD;

Craig Hopkinson , MD;

Ying Jiang , PhD;

Christine Graham , PhD;

Bernard Silverman , MD;

Lauren DiPetrillo , PhD;

Adam Simmons , MPH;

David McDonnell , MD;

Rene Kahn , MD, PhD;

Jiani Yin , PhD;

Vasudev Bhupathi , MBA;

10/08/2020

A Combination of Olanzapine and Samidorphan in Adults With Schizophrenia and Bipolar I Disorder: Overview of Clinical Data

Objectives: Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is hindered by significant weight gain. A combination of olanzapine and samidorphan...

Mark Todtenkopf , PhD;

Lauren DiPetrillo , PhD;

Hannah Cummings , PhD;

Leslie Citrome , MD;

Adam Simmons , MPH;

David McDonnell , MD;

Ying Jiang , PhD;

Lei Sun , PhD;

Christine Graham , PhD;

Bernard Silverman , MD;

10/08/2020

A Phase 3, Multicenter Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Olanzapine/Samidorphan in Patients With Schizophrenia

Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM), is in development for the treatment of schizophrenia and is intended to provide the antipsychotic efficacy of...

Christina Arevalo , MS;

Sergey Yagoda , PhD, MD;

Christine Graham , PhD;

Yangsong Cheng , PhD;

Adam Simmons , MPH;

David McDonnell , MD;

11/22/2019

Patient Preferences Concerning the Efficacy and Side Effect Profile of Schizophrenia Medication: A Survey of Patients Living With Schizophrenia

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: A survey was carried out to investigate the relative importance of an...

Eric Achtyes , MD;

Anna Skabeev , MD;

Ying Jiang , PhD;

Peter J. Weiden , MD, PhD;

Patricia Marcy , BSN;

Nikki Levy , BS ;

Adam Simmons , MPH;

03/01/2019

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients With Acute Exacerbation of Schizophrenia

Background: ALKS 3831, under development for the treatment of schizophrenia, is composed of olanzapine and samidorphan. In a prior study, samidorphan mitigated olanzapine-associated weigh...

Ying Jiang , PhD;

Bernard Silverman , MD;

Lauren DiPetrillo , PhD;

Steven Potkin , MD;

Adam Simmons , MPH;

David McDonnell , MD;

03/01/2019